Immunostimulatory monoclonal antibodies for cancer therapy

Increasing immune responses with immunostimulatory monoclonal antibodies (mAbs) directed to immune-receptor molecules is a new and exciting strategy in cancer therapy. This expanding class of agents functions on crucial receptors, either antagonizing those that suppress immune responses or activating others that amplify immune responses. Complications such as autoimmunity and systemic inflammation are problematic side effects associated with these agents. However, promising synergy has been observed in preclinical models using combinations of immunostimulatory antibodies and other immunotherapy strategies or conventional cancer therapies. Importantly, mAbs of this type have now entered clinical trials with encouraging initial results.

[1]  W. Zou.  Regulatory T cells, tumour immunity and immunotherapy , 2006, Nature Reviews Immunology.

[2]  宇野 友康.  Eradication of established tumors in mice by a combination antibody-based therapy , 2007 .

[3]  D. Pardoll,et al.  Does the immune system see tumors as foreign or self? , 2003, Annual review of immunology.

[4]  Lieping Chen,et al.  Amplification of tumor immunity by gene transfer of the co‐stimulatory 4‐1BB ligand: synergy with the CD28 co‐stimulatory pathway , 1998, European journal of immunology.

[5]  P. Matzinger.  The Danger Model: A Renewed Sense of Self , 2002, Science.

[6]  T. Hünig,et al.  Efficient expansion of regulatory T cells in vitro and in vivo with a CD 28 , 2003 .

[7]  Alexander Perl,et al.  A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. , 2006, Blood.

[8]  M. Little,et al.  Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 x CD19 tandem diabody, and CD28 costimulation. , 2000, Cancer research.

[9]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[10]  K. Flaherty,et al.  Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Fumito Ito,et al.  Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines , 2004, Cancer Research.

[12]  U. Grohmann,et al.  Modulation of tryptophan catabolism by regulatory T cells , 2003, Nature Immunology.

[13]  T. Mak,et al.  CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand , 1998, The Journal of experimental medicine.

[14]  N. Kawashima,et al.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  A. Dahlin,et al.  Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB , 2002, Nature Medicine.

[16]  Moses Rodriguez,et al.  Immunotherapeutic Potential of B7-DC (PD-L2) Cross-Linking Antibody In Conferring Antitumor Immunity , 2004, Cancer Research.

[17]  B. Kwon,et al.  Stimulation with 4-1 BB ( CD 137 ) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD 4 T cells , 2005 .

[18]  P. Linsley,et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.

[19]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Crystal,et al.  Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. , 2000 .

[21]  J. Egen,et al.  Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. , 2002, Immunity.

[22]  J. Allison,et al.  Checkpoint blockade in cancer immunotherapy. , 2007, Advances in immunology.

[23]  G. Alvord,et al.  Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1 , 2000, The Journal of Immunology.

[24]  T. Noda,et al.  Impairment of Antigen-Presenting Cell Function in Mice Lacking Expression of Ox40 Ligand , 2000, The Journal of experimental medicine.

[25]  Lieping Chen,et al.  NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. , 1998, Cellular immunology.

[26]  T. Watts,et al.  TNF/TNFR family members in costimulation of T cell responses. , 2005, Annual review of immunology.

[27]  T. Luft,et al.  IL-1β Enhances CD40 Ligand-Mediated Cytokine Secretion by Human Dendritic Cells (DC): A Mechanism for T Cell-Independent DC Activation1 , 2002, The Journal of Immunology.

[28]  S. Rosenberg,et al.  Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. , 2005, Journal of immunotherapy.

[29]  M. Croft.  Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? , 2003, Nature Reviews Immunology.

[30]  D. Pardoll,et al.  Cancer immunotherapy: breaking the barriers to harvest the crop , 2004, Nature Medicine.

[31]  Lieping Chen,et al.  Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells1 , 2002, The Journal of Immunology.

[32]  David Allman,et al.  Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB , 2002, Nature Biotechnology.

[33]  J. Madrenas,et al.  A molecular perspective of CTLA-4 function. , 2006, Annual review of immunology.

[34]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[35]  E. Jaffee,et al.  Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.

[36]  C. Anasetti,et al.  rapamycin Prevention of lethal acute GVHD with an agonistic CD 28 antibody and , 2004 .

[37]  P. Lollini,et al.  Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti‐OX40 and anti‐4‐1BB monoclonal antibodies induces T cell–mediated protective immunity in Her‐2/neu transgenic mice , 2005, International journal of cancer.

[38]  M. Bachmann,et al.  Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. , 1999, Journal of immunology.

[39]  M. Glennie,et al.  T Cell Immunity to Lymphoma Following Treatment with Anti-CD40 Monoclonal Antibody1 , 2002, The Journal of Immunology.

[40]  Z. Lee,et al.  Immune Responses in 4-1BB (CD137)-Deficient Mice1 , 2002, The Journal of Immunology.

[41]  Lieping Chen,et al.  Immunomodulatory gene therapy with interleukin 12 and 4-1BB ligand: long- term remission of liver metastases in a mouse model. , 2000, Journal of the National Cancer Institute.

[42]  B. Kwon,et al.  Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. , 2006, International immunology.

[43]  Lieping Chen,et al.  Anti-4-1 BB Monoclonal Antibody Enhances Rejection of Large Tumor Burden by Promoting Survival but not Clonal Expansion of Tumor-specific CD 8 T Cells 1 , 2002 .

[44]  M. Bachmann,et al.  OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection. , 1999, Immunity.

[45]  S. Rosenberg,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Drazen.  Volunteers at risk. , 2006, The New England journal of medicine.

[47]  A. Takaoka,et al.  Comparing antibody and small-molecule therapies for cancer , 2006, Nature Reviews Cancer.

[48]  D. Pardoll,et al.  B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.

[49]  J. Reuben,et al.  Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma , 2006, Cancer.

[50]  C. Reis e Sousa.  Dendritic cells in a mature age , 2006, Nature reviews. Immunology.

[51]  N. Copeland,et al.  Molecular cloning of a ligand for the inducible T cell gene 4‐1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor , 1993, European journal of immunology.

[52]  Lieping Chen,et al.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors , 1997, Nature Medicine.

[53]  J. Gribben,et al.  Phase I study of recombinant human CD40 ligand in cancer patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[55]  Moses Rodriguez,et al.  Cross-linking the B7 Family Molecule B7-DC Directly Activates Immune Functions of Dendritic Cells , 2002, The Journal of experimental medicine.

[56]  Eli Gilboa,et al.  The promise of cancer vaccines , 2004, Nature Reviews Cancer.

[57]  J. Prieto,et al.  Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  W. Blackwelder,et al.  Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer , 2005, Nature Medicine.

[59]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[60]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[61]  S. Rosenberg,et al.  Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. , 2004, Journal of immunotherapy.

[62]  R. Mittler,et al.  Anti–4-1bb Monoclonal Antibodies Abrogate T Cell–Dependent Humoral Immune Responses in Vivo through the Induction of Helper T Cell Anergy , 1999, The Journal of experimental medicine.

[63]  J. Allison,et al.  Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. , 1993, Science.

[64]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[65]  A. Korman,et al.  Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques , 2003, The Journal of Immunology.

[66]  M. Colombo,et al.  Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. , 2006, Cancer research.

[67]  K. Flaherty,et al.  Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  S. Thung,et al.  Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[69]  M. Debenedette,et al.  4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine. , 1999, Journal of immunology.

[70]  C. Su,et al.  Apoptosis of multiple myeloma cells induced by agonist monoclonal antibody against human CD28. , 2005, Cellular immunology.

[71]  Lieping Chen,et al.  Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. , 2002, Cancer research.

[72]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study , 2005, Annals of Surgical Oncology.

[73]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[74]  S. Rosenberg,et al.  Adoptive immunotherapy for cancer: building on success , 2006, Nature Reviews Immunology.

[75]  S. Quezada,et al.  CD40/CD154 interactions at the interface of tolerance and immunity. , 2004, Annual review of immunology.

[76]  F. Hodi,et al.  Combinatorial cancer immunotherapy. , 2006, Advances in immunology.

[77]  D. Jarjoura,et al.  Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. , 2006, Cancer research.

[78]  J. Bluestone,et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. , 1995, Immunity.

[79]  J. Altman,et al.  In vivo stimulation of CD137 broadens primary antiviral CD8+ T cell responses , 2002, Nature Immunology.

[80]  Aaron J. Johnson,et al.  Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. , 2002, The Journal of clinical investigation.

[81]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[82]  M. Meseck,et al.  OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[83]  A. Aruffo,et al.  4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses , 1997, The Journal of experimental medicine.

[84]  M. Croft,et al.  Signaling through OX40 (CD134) breaks peripheral T-cell tolerance , 2001, Nature Medicine.

[85]  G. Winter,et al.  Humanized antibodies. , 1993, Immunology today.

[86]  B. Foster,et al.  Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. , 2000, Cancer research.

[87]  R. Gold,et al.  Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis , 2005, The Journal of experimental medicine.

[88]  B. Kwon,et al.  Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells. , 2005, Blood.

[89]  K. Sugamura,et al.  Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. , 2004, Cancer research.

[90]  Lieping Chen.  Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity , 2004, Nature Reviews Immunology.

[91]  J. Peschon,et al.  Ligation of 4-1BB (CDw137) Regulates Graft-Versus-Host Disease, Graft-Versus-Leukemia, and Graft Rejection in Allogeneic Bone Marrow Transplant Recipients1 , 2001, The Journal of Immunology.

[92]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[93]  J. Bluestone,et al.  Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. , 1998, Cancer research.

[94]  J. Wargo,et al.  Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy , 2004, Journal of immunotherapy.

[95]  P. Scherle,et al.  Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors , 2006, Nature Reviews Cancer.

[96]  T. Illidge,et al.  Anti-CD40 monoclonal antibody , 2005, Leukemia & lymphoma.

[97]  V. Bedian,et al.  In vivo efficacy of the CD40 agonist antibody CP-870,893 against a broad range of tumor types: Impact of tumor CD40 expression, dendritic cells, and chemotherapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  J. Cheville,et al.  Tumor B 7-H 1 Is Associated with Poor Prognosis in Renal Cell Carcinoma Patients with Long-term Follow-up , 2006 .

[99]  Michel C Nussenzweig,et al.  Tolerogenic dendritic cells. , 2003, Annual review of immunology.

[100]  F. Hodi.  Cytotoxic T-Lymphocyte–Associated Antigen-4 , 2007, Clinical Cancer Research.

[101]  Y. Inuyama,et al.  Induction of CTL Responses by Simultaneous Administration of Liposomal Peptide Vaccine with Anti-CD40 and Anti-CTLA-4 mAb1 , 2000, The Journal of Immunology.

[102]  D. McMillin,et al.  Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy. , 2006, Human gene therapy.

[103]  M. Croft.  Costimulation of T cells by OX40, 4-1BB, and CD27. , 2003, Cytokine & growth factor reviews.

[104]  Lieping Chen,et al.  Improving efficacy of interleukin‐12‐transfected dendritic cells injected into murine colon cancer with anti‐CD137 monoclonal antibodies and alloantigens , 2004, International journal of cancer.

[105]  B. Kwon,et al.  Functional Dichotomy between OX40 and 4-1BB in Modulating Effector CD8 T Cell Responses1 , 2006, The Journal of Immunology.

[106]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[107]  G. Zhu,et al.  Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo. , 2004, Blood.

[108]  B. Comin-Anduix,et al.  Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[109]  D. Porter,et al.  A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD 3 / CD 28 costimulation , 2006 .

[110]  S. Groshen,et al.  Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[112]  M. Glennie,et al.  CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help , 1999, Nature Medicine.

[113]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[114]  D. Kelvin,et al.  The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells. , 2005, Blood.

[115]  L. Rassenti,et al.  CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. , 2000, Blood.

[116]  H. Griesser,et al.  Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4 , 1995, Science.

[117]  L. Rassenti,et al.  CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. , 2000, Blood.

[118]  S. Bromley,et al.  The immunological synapse. , 2001, Annual review of immunology.

[119]  J. Cheville,et al.  Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. , 2006, Cancer research.

[120]  J. Allison,et al.  Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation , 1999, The Journal of experimental medicine.

[121]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[122]  A. Vella,et al.  Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation. , 2005, Trends in immunology.

[123]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[124]  Oreste Acuto,et al.  CD28-mediated co-stimulation: a quantitative support for TCR signalling , 2003, Nature Reviews Immunology.

[125]  T. Okazaki,et al.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.

[126]  N. Lonberg,et al.  High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. , 1996, Nature biotechnology.

[127]  K. Pollok,et al.  Inducible T cell antigen 4-1BB. Analysis of expression and function. , 1993, Journal of immunology.

[128]  C. Sheridan,et al.  TeGenero fiasco prompts regulatory rethink , 2006, Nature Biotechnology.

[129]  C. Thompson,et al.  T-cell regulation by CD28 and CTLA-4 , 2001, Nature Reviews Immunology.

[130]  C. Takahashi,et al.  Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal. , 1999, Journal of immunology.

[131]  S. Buus,et al.  Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4. , 2006, Cancer letters.

[132]  Lieping Chen,et al.  Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. , 2005, Vaccine.